Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA gives fast track status to axalimogene filolisbac

July 22, 2016

Helix BioPharma subsidiary finalizes Polish grant funding to support development of V-DOS47

July 22, 2016

Nascent Biotech licenses rights for pritumumab to Hisun in China

July 21, 2016

Cell Medica's CMD-003 obtains European orphan drug designation

July 21, 2016

Jounce Therapeutics and Celgene establish immuno-oncology collaboration

July 20, 2016

Helix BioPharma and NRC enter agreement in principle to collaborate on immuno-oncology initiatives

July 19, 2016

The EMA classifies AXAL as advanced therapy medicinal product

July 19, 2016

Nivolumab marketing applications accepted for filing

July 19, 2016

Targeting RANK pathway for breast cancer prevention in BRCA1-mutation carriers

July 19, 2016

Pierre Fabre Medicament discloses humanized antibodies for cancer therapy

July 19, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...